Karyopharm Therapeutics Inc. Stock Analysis & AI Score
Karyopharm Therapeutics Inc. (KPTI) has an ST Score of 48.2 (C+), driven by its Growth (A) and held back by its Momentum (D+). Analysts rate it Buy with a $9.50 price target (+2549.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIKPTI Stock Price History
KPTI Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
KPTI Latest Stock News
ST Score
Karyopharm Therapeutics Inc. (KPTI) has an ST Score of 48.2 (C+), driven by its Growth (A) and held back by its Momentum (D+). Analysts rate it Buy with a $9.50 price target (+2549.2% upside).
- Strongest
- GrowthA
- Weakest
- MomentumD+
All factor grades
- GrowthA
- ForecastB+
- ProfitabilityB
- ValuationC
- Financial StrengthC-
- MomentumD+
- Piotroski2/9
Press Releases
Company Contact Details
KPTI stock: frequently asked questions
What is KPTI's ST Score?
Karyopharm Therapeutics Inc. (KPTI) has an ST Score of 48.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KPTI a buy, hold, or sell?
Analysts rate KPTI a Buy, with a price target of $9.50 (+2549.2% vs the current price). Our ST Score grades it C+ (48.2/100). The ST Score is a data-driven signal, not a recommendation.
What are KPTI's factor grades?
Valuation C, Profitability B, Financial Strength C-, Momentum D+, Growth A, Forecast B+.
What is KPTI's valuation grade?
Karyopharm Therapeutics Inc. (KPTI) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KPTI's growth grade?
Karyopharm Therapeutics Inc. (KPTI) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KPTI's profitability grade?
Karyopharm Therapeutics Inc. (KPTI) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KPTI's financial strength grade?
Karyopharm Therapeutics Inc. (KPTI) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KPTI?
The average analyst price target for Karyopharm Therapeutics Inc. (KPTI) is $9.50 from 20 analysts, which is +2549.2% versus the recent price of $0.36.
What is KPTI's Piotroski score?
Karyopharm Therapeutics Inc. (KPTI) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.